The content on this site is intended for healthcare professionals only
Dr Bisogno speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.
For those receiving the low dose chemotherapy following initial treatments, 5 year overall survival improved from 73.7% to 86.5%, which is the first improvement in this indication for more than 30 years.
For more detail, watch Dr Bisogno present the data in a press conference here, or read our news coverage here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
